RV6153

RV6153 is an investigational small molecule drug developed by RespiVert Ltd. It acts as a dual inhibitor of phosphatidylinositol 3 kinase gamma (PI3Kγ) and delta (PI3Kδ). The drug was designed for inhaled administration to target respiratory diseases, specifically uncontrolled asthma and chronic obstructive pulmonary disease (COPD). Its mechanism involves inhibition of PI3Kγ and PI3Kδ isoforms, which are implicated in inflammatory pathways relevant to airway diseases. Clinical development included Phase 1 trials assessing safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers as well as subjects with stable asthma. Development has since been discontinued[1][2][3].

Other names

2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)benzonitrile